Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goflikicept and Olokizumab in Adult-Onset Still's Disease
NCT07625384Phase 3Not yet recruiting
- Sponsor
- R-Pharm
- Start
- May 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of goflikicept, olokizumab in adult-onset Still's disease (AOSD), sponsored by R-Pharm. Planned start May 2026; status: not yet recruiting.
02
Drugs
goflikiceptolokizumab
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT07625384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625384.